Kisqali

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Viambatanisho vya kazi:

ribociclib succinate

Inapatikana kutoka:

Novartis Europharm Limited

ATC kanuni:

L01XE

INN (Jina la Kimataifa):

ribociclib

Kundi la matibabu:

Antineoplastic agents

Eneo la matibabu:

Breast Neoplasms

Matibabu dalili:

Kisqali is indicated for the treatment of women with hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonist.

Bidhaa muhtasari:

Revision: 14

Idhini hali ya:

Authorised

Idhini ya tarehe:

2017-08-22

Taarifa za kipeperushi

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Kisqali 200 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains ribociclib succinate, equivalent to
200 mg ribociclib.
Excipients with known effect
Each film-coated tablet contains 0.344 mg soya lecithin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Light greyish violet, unscored, round, curved with bevelled edges
(approximate diameter: 11.1 mm),
debossed with “RIC” on one side and “NVR” on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Kisqali is indicated for the treatment of women with hormone receptor
(HR)-positive, human
epidermal growth factor receptor 2 (HER2)-negative locally advanced or
metastatic breast cancer in
combination with an aromatase inhibitor or fulvestrant as initial
endocrine-based therapy, or in women
who have received prior endocrine therapy.
In pre- or perimenopausal women,
_ _
the endocrine therapy should be combined with a luteinising
hormone-releasing hormone (LHRH) agonist.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment with Kisqali should be initiated by a physician experienced
in the use of anticancer
therapies.
Posology
The recommended dose is 600 mg (three 200 mg film-coated tablets) of
ribociclib once daily for
21 consecutive days followed by 7 days off treatment, resulting in a
complete cycle of 28 days. The
treatment should be continued as long as the patient is deriving
clinical benefit from therapy or until
unacceptable toxicity occurs.
Kisqali should be used together with 2.5 mg letrozole or another
aromatase inhibitor or with 500 mg
fulvestrant.
3
When Kisqali is used in combination with an aromatase inhibitor, the
aromatase inhibitor should be
taken orally once daily continuously throughout the 28-day cycle.
Please refer to the Summary of
Product Characteristics (SmPC) of the aromatase inhibitor for
additional details.
When Kisqali is used in combination with fulvest

Tabia za bidhaa

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Kisqali 200 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains ribociclib succinate, equivalent to
200 mg ribociclib.
Excipients with known effect
Each film-coated tablet contains 0.344 mg soya lecithin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Light greyish violet, unscored, round, curved with bevelled edges
(approximate diameter: 11.1 mm),
debossed with “RIC” on one side and “NVR” on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Kisqali is indicated for the treatment of women with hormone receptor
(HR)-positive, human
epidermal growth factor receptor 2 (HER2)-negative locally advanced or
metastatic breast cancer in
combination with an aromatase inhibitor or fulvestrant as initial
endocrine-based therapy, or in women
who have received prior endocrine therapy.
In pre- or perimenopausal women,
_ _
the endocrine therapy should be combined with a luteinising
hormone-releasing hormone (LHRH) agonist.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment with Kisqali should be initiated by a physician experienced
in the use of anticancer
therapies.
Posology
The recommended dose is 600 mg (three 200 mg film-coated tablets) of
ribociclib once daily for
21 consecutive days followed by 7 days off treatment, resulting in a
complete cycle of 28 days. The
treatment should be continued as long as the patient is deriving
clinical benefit from therapy or until
unacceptable toxicity occurs.
Kisqali should be used together with 2.5 mg letrozole or another
aromatase inhibitor or with 500 mg
fulvestrant.
3
When Kisqali is used in combination with an aromatase inhibitor, the
aromatase inhibitor should be
taken orally once daily continuously throughout the 28-day cycle.
Please refer to the Summary of
Product Characteristics (SmPC) of the aromatase inhibitor for
additional details.
When Kisqali is used in combination with fulvest